MHC Class I and MHC Class II Molecules
Why It Matters
MHC molecules dictate whether transplanted tissue is accepted and shape vaccine and immunotherapy efficacy, making them essential knowledge for clinicians and biotech developers.
Key Takeaways
- •MHC class I presents intracellular peptides to CD8 cytotoxic T cells.
- •MHC class II displays extracellular peptides to CD4 helper T cells.
- •Class I genes encode HLA‑A, B, C; found on all nucleated cells.
- •Class II genes encode HLA‑DP, DQ, DR; restricted to antigen‑presenting cells.
- •MHC compatibility determines transplant success and drives immune surveillance.
Summary
The video explains the two major families of major histocompatibility complex (MHC) molecules—class I and class II—and their central role in the adaptive immune response. It outlines how MHC genes on chromosome 6 encode human leukocyte antigens (HLA) that act as molecular “silver platters” displaying peptide fragments for T‑cell surveillance. Class I molecules (HLA‑A, B, C) are expressed on virtually every nucleated cell and present 8‑10‑amino‑acid peptides derived from intracellular proteins via the endogenous pathway, involving proteasomal degradation, TAP transport, and loading in the endoplasmic reticulum. In contrast, class II molecules (HLA‑DP, DQ, DR) appear only on professional antigen‑presenting cells and display longer 14‑20‑amino‑acid peptides from extracellular sources through the exogenous pathway, using the invariant chain and endosomal processing. The presenter highlights structural details: class I’s α‑chain with a peptide‑binding groove and β2‑microglobulin support, versus class II’s α‑ and β‑chains each contributing to a larger groove. Analogies such as “taking the trash and putting it on the corner” illustrate how cells continuously sample internal proteins, enabling early detection of viral infection or malignancy. The video also stresses that HLA typing is critical for transplant compatibility. Understanding MHC biology informs transplant matching, vaccine design, and emerging immunotherapies that manipulate antigen presentation. Clinicians and researchers must grasp these pathways to predict immune responses, avoid graft rejection, and harness T‑cell activation for therapeutic benefit.
Comments
Want to join the conversation?
Loading comments...